https://www.selleckchem.com/pr....oducts/glycochenodeo
002), whereas the risk of any ICH, symptomatic ICH, parenchymal haematoma type 2, in-hospital mortality and 3-month mortality did not differ significantly (p0.05). No significant differences in reocclusion rate, recanalization rate or excellent functional outcome were found between the patients treated with or without tirofiban, but significantly favourable functional outcome at 3months occurred in the tirofiban group (p=0.017). Tirofiban administration in patients receiving EVT significantly improved 3-month favo
Like
Comment
Share
